Key takeaways
- Estradiol acts directly on endothelium — nitric oxide, inflammation, oxidative stress, blood pressure — not mainly through lipids.
- Cardiovascular risk in women converges with men's over roughly the decade after menopause.
- The 2002 WHI participants averaged well over a decade past menopause, and the result was applied to women it did not study.
- Within about ten years of menopause and without established disease, the cardiovascular arithmetic is favourable; later, it is not.
- Hormone therapy is prescribed for symptoms. It is not a cardiovascular prevention drug and no trial supports that use.
Before menopause, women have markedly fewer cardiovascular events than men of the same age. After it, that advantage erodes and eventually disappears. The most parsimonious explanation is estradiol — a hormone that acts directly on the vessel wall, not just on lipids — and its withdrawal. What makes this topic difficult is not the mechanism, which is well described, but the trial history, which produced a headline in 2002 that changed practice worldwide and took two decades to properly qualify.
What the pre-menopausal advantage looks like
Compared with men of similar age, pre-menopausal women have lower rates of myocardial infarction and stroke, lower hypertension prevalence, a more favourable lipid pattern, better measured endothelial function and lower inflammatory markers. The gap is large enough that cardiovascular disease in a woman under 50 without a genetic lipid disorder is genuinely unusual.
The advantage is not a female trait in general. It tracks estradiol exposure, and it is lost early in women who lose ovarian function early — after surgical oophorectomy or premature ovarian insufficiency — which is the strongest natural evidence that the hormone rather than the chromosome is doing the work.
How estradiol acts on the vessel wall
The protective effect is not mainly a lipid effect, which is the common misreading. Estrogen receptors are expressed on vascular endothelium and smooth muscle, and estradiol acts there directly:
- Nitric oxide. Estradiol increases endothelial nitric oxide synthase activity. Nitric oxide is the vasodilator that keeps arteries compliant, and it is also anti-adhesive — it discourages monocytes from sticking to the endothelium, which is the initiating step in plaque formation.
- Inflammation. Vascular inflammatory signalling is dampened, which slows the transition from a fatty streak to an active lesion.
- Lipids. HDL is supported and LDL handling modulated — a real effect, but a secondary one.
- Oxidative stress. Lower oxidative load means less LDL oxidation, and oxidised LDL is the form that macrophages take up to become foam cells.
- Blood pressure. Modulation of the renin-angiotensin system contributes to the lower hypertension rates.
Every item on that list describes an effect on a healthy vessel — maintaining a state rather than reversing a disease. Hold that distinction, because it is the key to the trial controversy below.
What changes at menopause, and how fast
The shift is not a single event on a single date. Through the transition, and for several years after, a cluster of changes arrives:
- LDL rises, triglycerides rise, and HDL becomes less functional even when the number holds
- Blood pressure climbs, and hypertension prevalence eventually meets or exceeds that of men
- Measured endothelial function declines
- Fat redistributes toward the visceral compartment, worsening insulin sensitivity
- Event rates accelerate
By roughly ten years post-menopause, cardiovascular risk has largely converged with men's (El Khoudary et al., Circulation 2020). The practical implication is that this is the decade in which a woman's cardiovascular risk should be assessed properly rather than assumed to be low — including ApoB rather than LDL cholesterol alone, blood pressure measured at home rather than once a year in a clinic, and Lp(a) checked once in a lifetime.
The 2002 result, and what was actually studied
The Women's Health Initiative reported harm from combined estrogen plus progestin, and prescribing collapsed worldwide within months (Rossouw et al., JAMA 2002). The trial was well conducted. The problem was that the population it studied was not the population the result was applied to.
- The average participant was well over a decade past menopause at enrolment, with a mean age in the sixties
- Many had established subclinical atherosclerosis, and a substantial proportion had other cardiovascular risk factors
- The preparations used — oral conjugated equine estrogen with medroxyprogesterone acetate — are not what most women are prescribed now, and the oral route in particular raises clotting factors through first-pass hepatic metabolism in a way transdermal delivery does not
What the trial answered was: does starting this preparation, in these women, at this age, prevent cardiovascular events? The answer was no. What it was taken to mean was: hormone therapy causes heart attacks in women. Those are different statements, and the second one drove practice for fifteen years. Longer follow-up of the same cohort reported no increase in all-cause or cause-specific mortality over the extended period (Manson et al., WHI long-term mortality follow-up).
The timing hypothesis, and why it is mechanistically coherent
The reconciliation that emerged is the timing hypothesis: hormone therapy begun within about ten years of the final menstrual period, or before age 60, in a woman without established cardiovascular disease, appears cardiovascular-neutral to beneficial. Begun substantially later, the benefit is absent and may reverse. Trials designed specifically to test this — measuring atherosclerosis progression in recently versus remotely menopausal women — support the split (Hodis et al., N Engl J Med 2016; Harman et al., Ann Intern Med 2014).
The mechanism makes this predictable rather than surprising. Every action listed earlier is protective of an intact endothelium. Applied to an artery that already contains established plaque, the same signalling meets a different substrate — one where a change in inflammatory tone or vascular reactivity can act on a lesion rather than prevent one. Estradiol is a maintenance hormone for the vessel wall, and maintenance is a poor description of what a diseased artery needs.
That is a mechanistic account of a clinical observation, not a proven causal explanation, and it should be read as the former. What is settled is that timing changes the result.
How this translates into a decision
The current consensus position, stated plainly:
- Hormone therapy is prescribed to treat symptoms — vasomotor symptoms, sleep disruption, genitourinary symptoms, bone protection. Cardiovascular neutrality within the window is a reassurance, not an indication.
- Nobody should start hormone therapy for the purpose of preventing heart disease. There is no trial supporting that use, and the interventions that do have that evidence — blood pressure control, ApoB lowering, not smoking, resistance training and cardiorespiratory fitness — are available regardless.
- Within roughly ten years of menopause and under 60, in a woman without established cardiovascular disease, the cardiovascular arithmetic is favourable and the decision turns on symptoms and personal history.
- Beyond that window, or with established disease, the evaluation is more careful and the route and preparation matter more. Transdermal delivery avoids the first-pass hepatic effect on clotting factors that oral estrogen carries.
- Any woman with a personal history of breast cancer, venous thromboembolism or stroke needs an individual assessment, not a general rule.
When to start HRT covers the timing decision in more detail, and HRT for women covers how the evaluation is structured. If you want that assessment done properly, the 60-second assessment routes it to a physician.
The clinical insight: the 2002 result was correct about the women it studied and was applied to women it did not study. The lasting damage was not to hormone therapy's reputation but to a generation of women who stopped a treatment that was managing their symptoms, on the basis of a risk estimate generated in a population a decade older than them.
Bottom line
Estradiol acts directly on the vessel wall — nitric oxide, inflammation, oxidative stress, blood pressure — and its loss at menopause is the most likely explanation for why women's cardiovascular risk converges with men's over the following decade. Hormone therapy started within about ten years of menopause, in a woman without established cardiovascular disease, appears cardiovascular-neutral or favourable; started long after, it does not, and the mechanism explains why. None of that makes it a cardiovascular prevention drug. It is prescribed for symptoms, and the cardiovascular evidence tells you whether the timing is reasonable, not whether it is indicated. That decision is made with a physician after individual evaluation.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
